Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease have?
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease has 137 citations in the OpenAlex counts ScholarIQ stores.
When was Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease published?
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease has 2011 year in the ScholarIQ index.
What is the open-access status of Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease?
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease has bronze oa status in the ScholarIQ index.
What is the DOI of Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease?
The DOI for Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease is on the source record.
What is the PMID of Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease?
The PMID for Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease is on the source record.
What is the OpenAlex record for Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease?
The OpenAlex for Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease is on the source record.